NASDAQ:MTEM - Molecular Templates Stock Price, Forecast & News

Molecular Templates' stock was trading at $13.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MTEM shares have increased by 1.1% and is now trading at $13.36. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Molecular Templates.

Molecular Templates is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Molecular Templates.

Molecular Templates Inc (NASDAQ:MTEM) issued its earnings results on Thursday, March, 12th. The biotechnology company reported ($0.41) EPS for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.05. The biotechnology company earned $6.20 million during the quarter, compared to analysts' expectations of $6.20 million. Molecular Templates had a negative net margin of 311.73% and a negative return on equity of 55.41%. View Molecular Templates' earnings history.

Shares of Molecular Templates reverse split on the morning of Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

4 Wall Street analysts have issued 12-month price objectives for Molecular Templates' stock. Their forecasts range from $12.00 to $22.00. On average, they anticipate Molecular Templates' stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 32.2% from the stock's current price. View analysts' price targets for Molecular Templates.

Press coverage about MTEM stock has been trending very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Molecular Templates earned a news impact score of 3.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutMolecular Templates.

Molecular Templates saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,806,900 shares, an increase of 39.0% from the February 27th total of 1,300,000 shares. Based on an average daily volume of 271,300 shares, the days-to-cover ratio is presently 6.7 days. Currently, 7.0% of the company's shares are short sold. View Molecular Templates' Current Options Chain.

Some companies that are related to Molecular Templates include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Amarin (AMRN), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Alibaba Group (BABA), SLS International (SLS) and ACADIA Pharmaceuticals (ACAD).

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MTEM stock can currently be purchased for approximately $13.36.

Molecular Templates has a market capitalization of $609.88 million and generates $22.27 million in revenue each year. The biotechnology company earns $-69,420,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Molecular Templates employs 68 workers across the globe. View additional information about Molecular Templates.

The official website for Molecular Templates is http://www.mtem.com/.

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]